Literature DB >> 18281283

Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.

Zhe Wang1, Baochun Zhang, Liqun Yang, Jane Ding, Han-Fei Ding.   

Abstract

Normal development of the immune system requires regulated processing of NF-kappaB2 p100 to p52, which activates NF-kappaB2 signaling. Constitutive production of p52 has been suggested as a major mechanism underlying lymphomagenesis induced by NF-kappaB2 mutations, which occur recurrently in a variety of human lymphoid malignancies. To test the hypothesis, we generated transgenic mice with targeted expression of p52 in lymphocytes. In contrast to their counterparts expressing the tumor-derived NF-kappaB2 mutant p80HT, which develop predominantly B cell tumors, p52 transgenic mice are not prone to lymphomagenesis. However, they are predisposed to inflammatory autoimmune disease characterized by multiorgan infiltration of activated lymphocytes, high levels of autoantibodies in the serum, and immune complex glomerulonephritis. p52, but not p80HT, represses Bim expression, leading to defects in apoptotic processes critical for elimination of autoreactive lymphocytes and control of immune response. These findings reveal distinct signaling pathways for actions of NF-kappaB2 mutants and p52 and suggest a causal role for sustained NF-kappaB2 activation in the pathogenesis of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281283      PMCID: PMC3762532          DOI: 10.1074/jbc.M800806200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control.

Authors:  Z L Chu; T A McKinsey; L Liu; J J Gentry; M H Malim; D W Ballard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

2.  Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators.

Authors:  C C Chang; J Zhang; L Lombardi; A Neri; R Dalla-Favera
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

3.  Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors.

Authors:  T S Finco; A A Beg; A S Baldwin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

4.  Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells.

Authors:  E Dejardin; G Bonizzi; A Bellahcène; V Castronovo; M P Merville; V Bours
Journal:  Oncogene       Date:  1995-11-02       Impact factor: 9.867

5.  Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells.

Authors:  S Thakur; H C Lin; W T Tseng; S Kumar; R Bravo; F Foss; C Gélinas; A B Rabson
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

6.  Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions.

Authors:  J Zhang; C C Chang; L Lombardi; R Dalla-Favera
Journal:  Oncogene       Date:  1994-07       Impact factor: 9.867

7.  The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines.

Authors:  V Bours; E Dejardin; F Goujon-Letawe; M P Merville; V Castronovo
Journal:  Biochem Pharmacol       Date:  1994-01-13       Impact factor: 5.858

8.  Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies.

Authors:  A Migliazza; L Lombardi; M Rocchi; D Trecca; C C Chang; R Antonacci; N S Fracchiolla; P Ciana; A T Maiolo; A Neri
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

9.  Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture.

Authors:  G Franzoso; L Carlson; L Poljak; E W Shores; S Epstein; A Leonardi; A Grinberg; T Tran; T Scharton-Kersten; M Anver; P Love; K Brown; U Siebenlist
Journal:  J Exp Med       Date:  1998-01-19       Impact factor: 14.307

10.  Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2.

Authors:  H Ishikawa; D Carrasco; E Claudio; R P Ryseck; R Bravo
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

View more
  28 in total

Review 1.  Role of T cell-nuclear factor κB in transplantation.

Authors:  Luciana L Molinero; Maria-Luisa Alegre
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

Review 2.  Cell Death Pathways in Lymphoid Malignancies.

Authors:  Luke Fletcher; Edward Nabrinsky; Tingting Liu; Alexey Danilov
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

3.  NF-κB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-κB pathways.

Authors:  Minjun Yu; Xiulan Qi; Jose L Moreno; Donna L Farber; Achsah D Keegan
Journal:  J Immunol       Date:  2011-07-06       Impact factor: 5.422

4.  The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.

Authors:  J Claire Godbersen; Leigh Ann Humphries; Olga V Danilova; Peter E Kebbekus; Jennifer R Brown; Alan Eastman; Alexey V Danilov
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531

5.  The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

Authors:  Stuart J Gallagher; Branka Mijatov; Dilini Gunatilake; Jessamy C Tiffen; Kavitha Gowrishankar; Lei Jin; Gulietta M Pupo; Carleen Cullinane; Rab K Prinjha; Nicholas Smithers; Grant A McArthur; Helen Rizos; Peter Hersey
Journal:  J Invest Dermatol       Date:  2014-06-06       Impact factor: 8.551

6.  Loss of negative feedback control of nuclear factor-kappaB2 activity in lymphocytes leads to fatal lung inflammation.

Authors:  Liqun Yang; Hongjuan Cui; Zhe Wang; Baochun Zhang; Jane Ding; Lin Liu; Han-Fei Ding
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

Review 7.  The noncanonical NF-κB pathway.

Authors:  Shao-Cong Sun
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

8.  Substrate complex competition is a regulatory motif that allows NFκB RelA to license but not amplify NFκB RelB.

Authors:  Simon Mitchell; Alexander Hoffmann
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-02       Impact factor: 11.205

9.  NF-κB and cancer: a paradigm of Yin-Yang.

Authors:  Gutian Xiao; Jing Fu
Journal:  Am J Cancer Res       Date:  2010-12-06       Impact factor: 6.166

Review 10.  PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor.

Authors:  Ugur Hodoglugil; Michelle W Carrillo; Joan M Hebert; Niki Karachaliou; Rafael C Rosell; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-11       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.